TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.158nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Agonist activity at CXCR3 (unknown origin)More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Agonist activity at CCR10 (unknown origin)More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.251nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.251nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.251nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.316nMAssay Description:Agonist activity at CCR9 (unknown origin)More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.398nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.398nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.398nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.398nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.501nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.501nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.501nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.501nMAssay Description:Antagonist activity at CXCR5 (unknown origin)More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.631nMAssay Description:Agonist activity at CXCR7 (unknown origin)More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.631nMAssay Description:Agonist activity at CCR8 (unknown origin)More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 0.794nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 0.794nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Agonist activity at CXCR4 (unknown origin)More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Antagonist activity at CXCR1 (unknown origin)More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 1.60nMAssay Description:Agonist activity at CCR2 (unknown origin)More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 1.60nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 1.60nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Agonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as induction of beta-arrest...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 2.5nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 2.5nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 3.20nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 3.20nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 3.20nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 3.20nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetC-X-C chemokine receptor type 2(Homo sapiens (Human))
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Gsk Pharmaceuticals R & D
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV pro...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair